Enovis CORP (ENOV) Q4 2025 10-Q Quarterly Report
Filed: Nov 6, 2025Period ending Oct 3, 2025
Health Care
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSEC EDGAR Enovis CORP (ENOV) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Oct 3, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Enovis CORP Q4 2025 10-Q Analysis
Risk Factors
- • New Goodwill impairment risk triggered by 40% stock price decline, recognized $541M impairment Q3 2025 due to sustained market capitalization decrease
- • Updated impairment risk: total $1.186B Goodwill impairments recognized including $645M in 2024 annual test and $541M in 2025 interim assessment
Get deeper insights on Enovis CORP
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.